News
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
12 Mar 24
News, Price Target, Markets, Analyst Ratings, Trading Ideas
Mizuho Maintains Buy on Vaxcyte, Raises Price Target to $113
12 Mar 24
News, Price Target, Analyst Ratings
Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
4 Mar 24
Biotech, News, General
Needham Maintains Buy on Vaxcyte, Raises Price Target to $95
28 Feb 24
News, Price Target, Analyst Ratings
Recap: Vaxcyte Q4 Earnings
27 Feb 24
Earnings
Vaxcyte Q4 2023 GAAP EPS $(1.82) Misses $(1.07) Estimate
27 Feb 24
Earnings, Earnings Misses, News
Earnings Scheduled For February 27, 2024
27 Feb 24
Earnings
Vaxcyte Prices $750M Public Offering Of 10,937,500 Common Shares At $64/Share
31 Jan 24
News
Vaxcyte Commences Proposed Public Offering Of Common Stock And Pre-Funded Warrants; Terms Not Disclosed
30 Jan 24
News, Offerings
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
5 Jan 24
Analyst Color, Equities, News, Price Target, Reiteration, Small Cap, Markets, Analyst Ratings, Trading Ideas, General
Vaxcyte Provides Clinical And Regulatory Progress Update On Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise
4 Jan 24
Biotech, News, General
B of A Securities Maintains Buy on Vaxcyte, Raises Price Target to $80
2 Jan 24
News, Price Target, Analyst Ratings
Press releases
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
Earnings, Press Releases
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2 Feb 24
Health Care, Press Releases
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
1 Feb 24
News, Press Releases
Vaxcyte Announces Pricing of $750 Million Public Offering
30 Jan 24
Markets, Press Releases
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
30 Jan 24
News, Financing, Press Releases
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
29 Jan 24
Health Care, Press Releases, General
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 Jan 24
News, Management, Press Releases
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
4 Jan 24
Health Care, Press Releases